Chronic Heart Failure | Treatment Algorithms | Claims Data Analysis | US | 2017 November
First-line treatment of chronic heart failure (CHF) usually involves a beta blocker, an angiotensin-converting enzyme (ACE) inhibitor, and an oral diuretic. Second- or third-line treatments are often needed to better manage the disease. Physicians have numerous drug classes to choose from, most of which consist of drug options. The CHF market is heavily genericized, as such physician practice is minimally impacted by pricing pressures. The CHF Treatment Algorithm offers insight into prescribing patterns in this multi-layered treatment landscape where few branded agents jostle for patient share in a crowded sector. That said, small patient shares for such a prevalent indication can translate into significant commercial positions.
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
